La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Erasca a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Erasca..

Erasca (NASDAQ:ERAS) Azioni, Catena delle Opzioni

Erasca

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.

Erasca Inc

Barclays analyst Seth Sigman maintains Walmart (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>) with a Overweight and raises the price target from $78 to $90.

News

Price Target

Analyst Ratings

Barclays Maintains Overweight on Walmart, Raises Price Target to $90

WIIM

PMAX

Powell Max shares are trading higher after the company secured a $40 million equity line of credit with Yorkville Advisors to enhance liquidity and support strategic investments.

AMIX

Autonomix Medical shares are trading lower after the company announced the pricing of a $9 million underwritten public offering.

Barclays analyst Adrienne Yih maintains Gap (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GAP#NYSE">GAP</a>) with a Overweight and raises the price target from $31 to $32.

Barclays Maintains Overweight on Gap, Raises Price Target to $32

Powell Max Secures $40M Equity Line Of Credit With Yorkville Advisors To Enhance Liquidity Solutions And Support Strategic Investments

Boxing legend Floyd Mayweather Jr. is expanding his real estate empire with a major stake in 601W Companies&#8217; $10 billion office portfolio, marking his latest move in commercial property investment. According to The Real Deal, the deal, announced just weeks after his $402 million apartment portfolio acquisition, gives him partial ownership of 18 buildings totaling 10 million square feet.
Don't Miss:
<ul>
<li>During market downturns, investors are learning that unlike equities, these<a href="https://www.benzinga.com/money/connect-invest-real-estate-notes"> high-yield real estate notes that pay 7.5% &#8211; 9% are protected by resilient assets, buffering against losses.</a></li>
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> you can become an investor for $0.80 per share today.</a></li>
</ul>
While specific financial terms remain confidential, a source close to the deal described it as Mayweather&#8217;s &#8220;most significant&#8221; investment. The former world champion, who has accumulated $1.1 billion in career earnings, previously invested over $100 million with office landlord SL Green.
The portfolio includes prominent properties like 410 10th Avenue in Hudson Yards, Chicago&#8217;s Aon Center and Old Post Office Building and the Harborside office complex in Jersey City. Mark Karasick, managing member of 601W, confirmed that Mayweather&#8217;s investment will support property repositioning efforts and new acquisitions. The firm seeks opportunities in distressed office properties across major metropolitan areas, including Chicago and New York.
According to the report, 601W Companies has successfully navigated post-pandemic challenges. At 410 10th Avenue, purchased for $952 million in late 2020, the property maintains sufficient rental income to cover its mortgage obligations through 2032 despite occupancy dropping to 65%<a href="https://www.benzinga.com/news/24/04/38475445/us-regulators-seize-republic-first-bancorp-fulton-bank-steps-in-as-buyer-amid-regional-banking-woes"> following First Republic Bank&#8217;s collapse</a>.
See Also: This Jeff Bezos-backed startup will allow you to <a href="https://www.benzinga.com/money/bezos-landlord-100-dollars">become a landlord in just 10 minutes, with minimum investments as low as $100 for properties like the Byer House from Stranger Things.</a>
The firm recently secured a $65 million loan on an $85 million Harborside property acquisition, reflecting continued lender confidence. While facing industrywide refinancing hurdles, 601W has successfully negotiated several workout arrangements, including a three-year extension on the Aon Center&#8217;s half-billion-dollar debt package and fresh equity injection for Chicago&#8217;s One South Wacker Drive.
&#8220;New York City is the center of the world,&#8221; Mayweather said in a statement. &#8220;A wise person once told me if you buy real estate in New York and hold on to it over the years, you will always make money and win.&#8221;
The investment follows Mayweather&#8217;s October agreement to purchase Black Spruce Management&#8217;s apartment portfolio, comprising over 60 rental buildings in what could become New York City&#8217;s largest real estate transaction of the year.
The <a href="https://www.benzinga.com/markets/24/10/41581902/boxing-great-floyd-money-mayweather-makes-400-million-investment-in-affordable-housing-portfolio">undefeated boxer&#8217;s expanding real estate portfolio</a> reflects growing investor interest in office properties despite persistent market uncertainty. His partnership with 601W Companies, known for trophy office ownership and redevelopment expertise, signals confidence in the sector&#8217;s post-pandemic recovery potential.
Read Next:
<ul>
<li>‘Scrolling to UBI': Deloitte's #1 fastest-growing software company allows users to earn money on their phones –<a href="https://www.benzinga.com/money/mode-mobile-2"> invest today with $1,000 for just $0.25/share</a></li>
<li>Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die." <a href="https://www.benzinga.com/money/connect-invest-real-estate-notes">These high-yield real estate notes that pay 7.5% &#8211; 9% make earning passive income easier than ever.</a></li>
</ul>
Image from Shutterstock

Real Estate

Mayweather Punches Into $10B Office Portfolio, Betting On Post-COVID Revival

With Five-Year Series A Warrants Exercisable At $6.54 Per Share

Offerings

Autonomix Medical Prices $9M Public Offering Of Common Stock And Pre-Funded Warrant Units At $6.54 Per Unit

Barclays analyst Alex Scott maintains Reinsurance Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RGA#NYSE">RGA</a>) with a Overweight and raises the price target from $250 to $255.

Barclays Maintains Overweight on Reinsurance Gr, Raises Price Target to $255

Virpax Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRPX#NASDAQ">VRPX</a>) saw its shares rise on Friday<a target="_blank" href="https://www.benzinga.com/premarket" rel="noreferrer noopener"> in the premarket session.</a>
Today, the company announced results from a Dose Range Finding (DRF) study for Probudur,<a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b42136987/virpax-announces-positive-results-for-the-swine-model-dose-range-finding-study-for-probudur" rel="noreferrer noopener"> its long-acting liposomal bupivacaine formulation.</a>
The study, conducted in minipigs, demonstrated that Probudur was well-tolerated with no adverse effects, supporting its potential for both immediate and extended pain relief. The DRF study was conducted to evaluate the tolerance of Probudur in an incisional wound healing model in minipigs. Probudur was injected locally into the tissue surrounding the incision area.
&#8220;The completion of these studies brings us another step closer to filing our Investigational New Drug Application (IND) for Probudur,&#8221; stated Jatinder Dhaliwal, Chief Executive Officer of Virpax.
According to&nbsp;<a target="_blank" href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw" rel="noreferrer noopener">Benzinga Pro</a>, VRPX stock has lost over 88% in the past year.
Also Read:<a target="_blank" href="https://www.benzinga.com/24/11/42133364/us-stocks-on-edge-but-likely-to-end-the-week-in-the-green-trumps-treasury-pick-in-focus-expert-says-case-for-fed-pause-in-december-getting-stronger" rel="noreferrer noopener"> US Stocks Set To Open Lower On Friday As Investors Eye Cyclical Stocks: Trump&#8217;s Treasury Pick In Focus, Expert Says Case For Fed Pause In December &#8216;Getting Stronger&#8217;</a>
Yesterday, the company announced the extension of its cooperative research and development agreement with the National Center for Advancing Translational Sciences (NCATS), part of the National Institutes of Health (NIH).
This collaboration will continue the development of Virpax&#8217;s promising product candidate, NES100, an intranasal peptide designed for the management of <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b42123188/virpax-announces-agreement-with-the-u-s-department-of-health-and-human-services-for-the-developmen" rel="noreferrer noopener">acute and chronic non-cancer pain.</a>
NES100 is a novel enkephalin-based drug, utilizing advanced nanotechnology to enhance delivery into the brain.
Enkephalin, a naturally occurring peptide, has pain-relieving properties but is difficult to administer effectively in its original form. Virpax&#8217;s proprietary Molecular Envelope Technology (MET) protects and facilitates the drug&#8217;s delivery through the olfactory nerve pathway to the brain, where it targets delta opioid receptors to suppress pain.
Notably, NES100 has shown promise in animal models without the risks of opioid tolerance, withdrawal, or addiction.
Jatinder Dhaliwal, CEO of Virpax, emphasized that the collaboration will aid Virpax in advancing NES100 through preclinical and clinical stages, potentially offering a safer alternative to opioids for managing pain.
This development marks an important step in Virpax&#8217;s strategy to address pain management while mitigating opioid-related risks, Dhaliwal highlighted.
Price Action: VRPX shares are trading higher by 55.7% to $0.9181 premarket at last check Friday.
Image via Unsplash
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42136530/whats-going-on-with-ehang-stock-today" target="_blank" rel="noreferrer noopener">What&#8217;s Going On With EHang Stock Today?</a></li>
</ul>

Equities

Markets

Movers

General

VRPX

Why Is Virpax Pharmaceuticals Stock Gaining On Friday?

Oppenheimer analyst Ian Zaffino maintains Kyndryl Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KD#NYSE">KD</a>) with a Outperform and raises the price target from $33 to $37.

Oppenheimer Maintains Outperform on Kyndryl Hldgs, Raises Price Target to $37

Barclays analyst Saket Kalia maintains Procore Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PCOR#NYSE">PCOR</a>) with a Equal-Weight and raises the price target from $66 to $78.

PCOR

Barclays Maintains Equal-Weight on Procore Technologies, Raises Price Target to $78

Barclays analyst Tim Long maintains NetApp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTAP#NASDAQ">NTAP</a>) with a Equal-Weight and raises the price target from $119 to $132.

NTAP

Barclays Maintains Equal-Weight on NetApp, Raises Price Target to $132

Oppenheimer analyst Scott Schneeberger maintains McGrath RentCorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGRC#NASDAQ">MGRC</a>) with a Outperform and raises the price target from $124 to $139.

MGRC

Oppenheimer Maintains Outperform on McGrath RentCorp, Raises Price Target to $139

Anthropic, OpenAI's close rival, has raised an additional $4 billion from Amazon, and has agreed to make Amazon Web Services — Amazon's cloud computing division — the sole place it'll train its flagship generative AI models.
Anthropic says that it's working with Annapurna Labs, AWS' chipmaking division, to develop future generations of Trainium accelerators, AWS' custom-built chips for training AI models.
"Our engineers work closely with Annapurna's chip design team to extract maximum computational efficiency from the hardware, which we plan to leverage to train our most advanced foundation models," Anthropic wrote in a blog post.
&nbsp;

AMZN

'Anthropic raises an additional $4B from Amazon, makes AWS is 'primary' cloud partner' - TechCrunch

MicroStrategy Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) is trading at an astonishing 256% <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42121525/microstrategy-surges-674-in-2024-5-etfs-that-benefit-from-mstrs-bitcoin-driven-growth">premium to the net asset value</a> (NAV) of its Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) holdings, according to research conducted by BitMEX. 
The analysis highlights the extreme valuation disparity between MicroStrategy's current market capitalization, driven by its <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42090657/microstrategy-upsizes-convertible-notes-offering-to-2-6-billion-for-bitcoin-purchases">aggressive Bitcoin acquisition strategy</a>, and the actual value of the Bitcoin it holds.
"MicroStrategy's premium is insane, perhaps in part driven by some financial regulators banning people from buying Bitcoin ETFs. These people are so desperate for Bitcoin exposure, they buy MSTR instead, despite the premium," BitMEX Research <a href="https://x.com/BitMEXResearch/status/1859559585301909660?t=3y9RoHG42xLs-hFTMl2vDg&amp;s=19">stated</a>.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42121376/strategic-bitcoin-reserve-wouldnt-require-new-taxpayer-dollars-says-sen-cynthia-lummis">Strategic Bitcoin Reserve Wouldn&#8217;t Require New Taxpayer Dollars, Says Sen. Cynthia Lummis</a>
<h3 class="wp-block-heading">Breaking Down the Numbers</h3>
MicroStrategy currently holds 331,200 bitcoin, valued at approximately $32.3 billion, assuming a Bitcoin price of $97,600.
However, with a fully diluted market cap of $115 billion and a share price of $474, the company's valuation significantly exceeds its Bitcoin holdings. 
This disparity reflects an implicit bet by investors on the company's ability to leverage its premium for further Bitcoin acquisitions.
BitMEX Research explored scenarios where MicroStrategy could theoretically align its Bitcoin per share value with its current trading price of $474, assuming the Bitcoin price remains constant at $97,600 and the premium persists. 
Under these conditions, MicroStrategy would need to:
<ul>
<li>Issue 157 million additional shares, raising $157 billion.</li>
<li>Accumulate 1.9 million Bitcoin in total holdings.</li>
<li>Reach a market capitalization of $674 billion, with a share price climbing to $1,685.</li>
</ul>
This iterative calculation assumes the company continues issuing new equity at a premium to acquire more Bitcoin, a strategy MicroStrategy has employed since 2020. 
"If the premium persists, the company can keep issuing new shares until the value of the Bitcoin per share equals the current share price," BitMEX Research added.
<h3 class="wp-block-heading">Premium Justified By Strategy?</h3>
While some argue that the premium reflects investor enthusiasm for indirect Bitcoin exposure, others view it as a speculative bubble. 
BitMEX Research emphasized that the premium may only remain sustainable if investors continue to believe in MicroStrategy's yield strategy. 
"At that point, with a $1,685 share price, people may need to think the premium will still remain for another round of this," the analysis stated.
The company's holdings position it as a major Bitcoin proxy, the 256% premium suggests that investors are paying a significant markup for exposure, far exceeding the actual value of its Bitcoin.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/government/regulations/24/11/42120607/gary-gensler-to-step-down-as-sec-chair-on-trumps-inauguration-day">Gary Gensler To Step Down As SEC Chair On Trump&#8217;s Inauguration Day</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

MSTR

MicroStrategy Trading At 'Insane' 256% Premium To Bitcoin Holdings, Research Shows

Barclays analyst Alex Scott maintains Manulife Financial (TSX:<a class="ticker" href="https://www.benzinga.com/stock/MFC#TSX">MFC</a>) with a Equal-Weight and raises the price target from C$39 to C$40.

TSX:MFC

Barclays Maintains Equal-Weight on Manulife Financial, Raises Price Target to C$40

GEHC

GE HealthCare Enhances OEC 3D C-Arm With Lung Suite And Expanded OEC Open Interface To Improve Imaging Precision And Workflow In Interventional Pulmonology

Buckle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKE#NYSE">BKE</a>) just disclosed its Q3 earnings on Friday, November 22, 2024 at 06:50 AM.
Here's a brief overview of the earnings report.
<h3>Earnings</h3>
Buckle beat estimated earnings by 5.0%, reporting an EPS of $0.88 versus an estimate of $0.84.
Revenue was down $9.84 million from the same period last year.
<h3>Earnings History Overview</h3>
The company beat on EPS by $0.02 in the previous quarter, leading to a 5.0% increase share price change the next day.
Here's a look at Buckle's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.76</td>
<td>0.74</td>
<td>1.44</td>
<td>0.98</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.78</td>
<td>0.69</td>
<td>1.59</td>
<td>1.04</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>272.42M</td>
<td>263.64M</td>
<td>383.63M</td>
<td>316.70M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>282.39M</td>
<td>262.48M</td>
<td>382.38M</td>
<td>303.46M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Buckle <a href="https://www.benzinga.com/quote/BKE/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

Buckle Q3 Earnings Assessment

US Politics
<ul>
<li><a href="https://www.benzinga.com/24/11/42131911/donald-trump-appointed-doge-to-have-marginal-impact-saving-50-100-billion-says-analyst-as-elon-musk-aims-to-target-500-billion-plus-in-federal-expenditures">Donald Trump&#8217;s DOGE Initiative To Have &#8216;Marginal Impact&#8217; Says Analyst As Elon Musk Aims To Target Over $500B In Federal Expenditures</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42131449/with-gary-gensler-preparing-to-quit-in-2025-secs-crypto-cases-likely-to-quietly-go-away-amid-trumps-pro-bitcoin-stance-says-pantera-capitals-katrina-paglia">As Gary Gensler Eyes 2025 Exit, SEC Crypto Cases Could &#8216;Quietly Disappear&#8217; Under Trump&#8217;s Pro-Bitcoin Agenda, Says Pantera Capital&#8217;s Katrina Paglia</a></li>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/42130859/as-trump-backs-drill-baby-drill-his-doge-co-lead-elon-musk-believes-all-energy-generation-will-be-solar-heres-what-ubs-recommends-after-election-dip">As Trump Backs &#8216;Drill Baby, Drill,&#8217; His DOGE Co-Lead Elon Musk Believes &#8216;All Energy Generation Will Be Solar&#8217; — Here&#8217;s What UBS Recommends After Election Dip</a></li>
<li><a href="https://www.benzinga.com/news/24/11/42130207/trump-picks-former-florida-ag-pam-bondi-for-justice-department-after-matt-gaetz-withdraws">Trump Picks Former Florida AG Pam Bondi For Justice Department After Matt Gaetz Withdraws</a></li>
</ul>
US Markets­­­­­­­­
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/42133820/potential-healthy-correction-for-an-expensive-market-looms-as-us-economic-growth-and-earnings-slow-says-asset-manager-sp-500-nasdaq-futures-trade-lower-in-premarket">Potential &#8216;Healthy Correction&#8217; For An &#8216;Expensive&#8217; Market Looms As US Economic Growth And Earnings Slow, Says Asset Manager: S&amp;P 500, Nasdaq Futures Trade Lower In Premarket</a></li>
<li><a href="https://www.benzinga.com/24/11/42133364/us-stocks-on-edge-but-likely-to-end-the-week-in-the-green-trumps-treasury-pick-in-focus-expert-says-case-for-fed-pause-in-december-getting-stronger">US Stocks Set To Open Lower On Friday As Investors Eye Cyclical Stocks: Trump&#8217;s Treasury Pick In Focus, Expert Says Case For Fed Pause In December &#8216;Getting Stronger&#8217;</a></li>
<li><a href="https://www.benzinga.com/24/11/42133339/why-elastic-shares-are-trading-higher-by-29-here-are-20-stocks-moving-premarket">Why Elastic Shares Are Trading Higher By 29%; Here Are 20 Stocks Moving Premarket</a></li>
<li><a href="https://www.benzinga.com/24/11/42131399/dow-surges-over-450-points-investor-sentiment-improves-fear-greed-index-moves-to-greed-zone">Dow Surges Over 450 Points As Nvidia Climbs Post-Earnings, Google, Amazon Slip: Fear Index Shifts To &#8216;Greed&#8217; Zone</a></li>
</ul>
Crypto
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42135319/dogecoin-up-3-shiba-inu-up-4-what-is-going-on">Dogecoin Up 3%, Shiba Inu Up 4%: What Is Going On?</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42134782/after-plunging-16-microstrategy-makes-modest-recovery-in-friday-pre-market-is-there-still-hope-for-a-100k-btc-effect">After Plunging 16%, MicroStrategy Makes Modest Recovery In Friday Pre-Market: Is There Still Hope For A $100K BTC Effect?</a></li>
<li><a href="https://www.benzinga.com/24/11/42130693/bitcoins-path-to-100k-inevitable-but-leverage-to-the-gills-warns-mike-novogratz-predicts-80k-correction-ahead">Bitcoin&#8217;s Path To $100K &#8216;Inevitable&#8217; But Crypto Community Is &#8216;Leveraged To The Gills,&#8217; Warns Galaxy&#8217;s Mike Novogratz, Predicts Correction To $80K Ahead</a></li>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/42127938/bitcoin-analyst-warns-of-4-6-flash-crashes-before-year-end-as-it-inches-closer-to-100k-thats-the-moment-altcoins-shoot-off">Bitcoin Analyst Warns Of &#8216;4-6 Flash Crashes&#8217; Before Year-End As It Inches Closer To $100K: That&#8217;s The Moment Altcoins &#8216;Shoot Off&#8217;</a></li>
</ul>
World Politics
<ul>
<li><a href="https://www.benzinga.com/news/global/24/11/42132984/texas-governor-mandates-state-agencies-to-divest-from-china-will-defend-and-safeguard-itself-from-any-potential-threat">Texas Governor Mandates State Agencies To Divest From China: &#8216;Will Defend And Safeguard Itself&#8230;From Any Potential Threat&#8217;</a></li>
</ul>
US Economy
<ul>
<li><a href="https://www.benzinga.com/24/11/42134031/markets-got-it-wrong-after-elections-prospects-of-tariffs-not-good-for-equities-vs-dollar-says-ex-goldman-sachs-analyst">Markets Misread Trump Win, Says Ex-Goldman Sachs Analyst: &#8216;Prospects Of Tariffs Not Good For Equities</a></li>
</ul>
World Economy
<ul>
<li><a href="https://www.benzinga.com/24/11/42135153/mexicos-increased-mining-royalties-could-deter-7-billion-in-foreign-investments">Mexico&#8217;s Increased Mining Royalties Could Deter $7 Billion In Foreign Investments</a></li>
<li><a href="https://www.benzinga.com/markets/forex/24/11/42134563/asia-mixed-europe-mostly-in-red-dollar-hits-13-month-high-global-markets-today-while-us-slept">Asia Mixed, Europe Mostly In Red; Dollar Hits 13-Month High &#8211; Global Markets Today While US Slept</a></li>
</ul>
Tech
<ul>
<li><a href="https://www.benzinga.com/24/11/42132292/mark-zuckerbergs-meta-takes-on-64b-pig-butchering-scams-targeting-people-through-dating-apps-social-media-crypto-investing-and-other-apps">Mark Zuckerberg&#8217;s Meta Cracks Down On $64B &#8216;Pig Butchering&#8217; Scams Involving Dating Apps, Social Media And Crypto Investing</a></li>
<li><a href="https://www.benzinga.com/news/global/24/11/42132104/huawei-to-launch-mate-70-smartphone-with-advanced-homegrown-chip-challenging-apple-in-china-amid-us-sanctions-report">Apple Faces New Challenge As Huawei Advances Domestic Chip Tech In Mate 70 Series Amid US Sanctions: Report</a></li>
<li><a href="https://www.benzinga.com/24/11/42131274/why-googles-chrome-battle-isnt-just-about-search-gene-munster-calls-it-a-tough-day-for-big-tech-on-the-regulatory-front">Google&#8217;s Chrome Battle Goes Beyond The Browser: Gene Munster Outlines Wider Implications Of DOJ Going After The Search Giant</a></li>
<li><a href="https://www.benzinga.com/news/global/24/11/42130782/amazon-at-risk-of-major-fine-as-eu-investigates-alleged-preference-for-in-house-products-under-digital-markets-act-report">Amazon At Risk Of Major Fine As EU Investigates Alleged Preference For In-House Products Under Digital Markets Act: Report</a></li>
<li><a href="https://www.benzinga.com/markets/24/11/42130303/chatgpt-parent-openai-considers-building-its-own-web-browser-to-challenge-googles-search-monopoly-following-doj-push-to-break-up-chrome-dominance">ChatGPT-Parent OpenAI Considers Building Its Own Web Browser To Challenge Google&#8217;s Search Monopoly, Following DOJ Push To Break Up Chrome Dominance</a></li>
<li><a href="https://www.benzinga.com/media/24/11/42129847/apple-prepares-to-take-on-openais-chatgpt-google-gemini-live-with-llm-siri-in-2025-report">Apple Prepares To Take On OpenAI&#8217;s ChatGPT, Google Gemini &#8216;Live&#8217; With LLM Siri In 2025: Report</a></li>
</ul>
Electric Vehicle
<ul>
<li><a href="https://www.benzinga.com/tech/24/11/42134370/hyundai-kia-recall-over-208000-electrified-vehicles-in-us-heres-more">Hyundai, Kia Recall Over 208,000 Electrified Vehicles In US: Here&#8217;s More</a></li>
<li><a href="https://www.benzinga.com/24/11/42132485/hyundais-incoming-ceo-is-steadfast-on-evs-says-tesla-ceo-elon-musks-proximity-to-trump-will-be-good-for-industry">Tesla CEO Elon Musk&#8217;s Proximity To Trump Will Benefit EV Industry, Says Incoming Hyundai CEO As He Shrugs Off Potential Tariff Threats</a></li>
<li><a href="https://www.benzinga.com/24/11/42131163/tesla-ceo-elon-musk-attempts-to-temper-down-expectations-of-30k-optimus-or-cybercab-soon">Tesla CEO Elon Musk Tries To Lower Expectations Of $30K Optimus Or Cybercab</a></li>
</ul>
Consumer
<ul>
<li><a href="https://www.benzinga.com/24/11/42135392/general-motors-gears-up-for-potential-f1-entry-in-2026-report">General Motors Gears Up For Potential F1 Entry In 2026: Report</a></li>
<li><a href="https://www.benzinga.com/24/11/42134177/pepsico-strengthens-hold-on-us-hummus-market-with-sabra-buyout">PepsiCo Strengthens Hold On US Hummus Market with Sabra &amp; Obela Buyout</a></li>
<li><a href="https://www.benzinga.com/markets/equities/24/11/42134097/gap-stock-surges-14-in-friday-pre-market-after-boosting-sales-forecast">GAP Stock Surges 14% In Friday Pre-Market After Boosting Sales Forecast</a></li>
<li><a href="https://www.benzinga.com/24/11/42131172/bath-here-are-the-recent-forecast-changes-from-wall-streets-most-accurate-analysts">Bath &amp; Body Works Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street&#8217;s Most Accurate Analysts</a></li>
</ul>
Communication
<ul>
<li><a href="https://www.benzinga.com/markets/24/11/42135459/web3-games-are-poised-to-surpass-console-gaming-by-2030-what-investors-need-to-know">Web3 Games Are Poised to Surpass Console Gaming by 2030: What Investors Need to Know</a></li>
<li><a href="https://www.benzinga.com/24/11/42132644/reddit-falls-7-in-afterhours-as-advance-plans-stake-sale-technicals-show-strong-support-but-selling-pressure-persists-at-overbought-levels">Reddit Tumbles 7% In Premarket Amid Advance&#8217;s Stake Sale Announcement: Technicals Show Strong Support, But Selling Pressure Persists At Overbought Levels</a></li>
</ul>
Industrial
<ul>
<li><a href="https://www.benzinga.com/general/travel/24/11/42131219/american-airlines-targets-gate-lice-with-new-boarding-tech-at-100-airports-this-holiday-season">American Airlines Targets &#8216;Gate Lice&#8217; With New Boarding Tech At 100+ Airports This Holiday Season</a></li>
</ul>
Financial
<ul>
<li><a href="https://www.benzinga.com/news/global/24/11/42129914/jim-cramer-doubles-down-on-nvidia-demand-is-accelerating-as-ai-customers-have-no-choice-but-to-buy-its-chips">Jim Cramer Doubles Down On Nvidia: &#8216;Demand Is Accelerating&#8217; As AI Customers &#8216;Have No Choice&#8217; But To Buy Its Chips</a></li>
</ul>
General
<ul>
<li><a href="https://www.benzinga.com/markets/24/11/42131413/gop-megadonor-ken-griffin-is-open-to-the-possibility-of-selling-minority-stake-in-citadel">GOP Megadonor Ken Griffin Is &#8216;Open To The Possibility&#8217; Of Selling Minority Stake In Citadel</a></li>
</ul>
Space
<ul>
<li><a href="https://www.benzinga.com/general/space/24/11/42133073/spacex-ceo-elon-musk-explains-how-starships-engine-design-prevents-chain-failures-unlike-soviet-n1-rocket">SpaceX CEO Elon Musk Explains How Starship&#8217;s Engine Design Prevents Chain Failures Unlike Soviet N1 Rocket</a></li>
</ul>
Photo by JOCA_PH on Shutterstock

$ETH

MicroStrategy Rebounds Slightly After 16% Drop: Can $100K Bitcoin Still Drive Growth? Trump Taps Ex-Florida AG Pam Bondi For DOJ After Gaetz Backs Out - Top Headlines Today While US Slept

<a href="https://www.sec.gov/newsroom/press-releases/2024-184" title="https://www.sec.gov/newsroom/press-releases/2024-184">https://www.sec.gov/newsroom/press-releases/2024-184</a>

UPS To Pay $45M Penalty For Improperly Valuing Business Unit - SEC

Erasca: New Focus After Restructuring, But Need More Differentiation

Erasca (ERAS) announced clinical progress for naporafenib and preclinical execution across the company's RAS targeting franchise. Shannon R. Morris...

Erasca announces clinical progress for naporafenib

Analyst Jeffrey Hung of Morgan Stanley maintained a Buy rating on Erasca (ERAS – Research Report), retaining the price target of $4.00. Jeffrey Hun...

Erasca's Strategic Advancements and Promising R&D Position it as a Buy

Alec Stranahan, an analyst from Bank of America Securities, maintained the Hold rating on Erasca (ERAS – Research Report). The associated price tar...

Erasca's Promising Developments Amid Uncertainties Justify Hold Rating

Capital One Financial analyst Naureen Quibria assigned a Buy rating on Erasca (ERAS – Research Report) today and set a price target of $4.00. Naure...

Erasca's Naporafenib Progress and Strategic Focus Bolster Buy Rating

Andres Y. Maldonado, an analyst from H.C. Wainwright, reiterated the Buy rating on Erasca (ERAS – Research Report). The associated price target rem...

Erasca's Innovative Naporafenib Shows Promise in NRAS-mutant Melanoma, Garnering Buy Rating from Analyst

Erasca reports Q3 results

Erasca, Inc. ( ($ERAS) ) has released its Q3 earnings. Here is a breakdown of the information Erasca, Inc. presented to its investors. Erasca, Inc....

Erasca, Inc. Reports Strong Progress in Oncology Pipeline

Bank of America Securities analyst Alec Stranahan maintained a Hold rating on Erasca (ERAS – Research Report) today. The company's shares closed ye...

Bank of America Securities Sticks to Its Hold Rating for Erasca (ERAS)

Jefferies initiated coverage of Erasca (ERAS) with a Buy rating and $6 price target. The firm sees appeal in the company's valuation, citing the co...

Erasca initiated with a Buy at Jefferies

AZNCF

DAWN

ERAS

NVSEF

RVMD

Press Releases

Erasca Announces Strategic In-Licensing of RAS-Targeting Franchise

Health Care

Financing

Erasca Announces Closing of Underwritten Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Erasca to Present at Upcoming Investor Conferences in June

Erasca Initiates SEACRAFT-2 Pivotal Phase 3 Trial Evaluating Naporafenib Plus Trametinib in Patients with NRAS-Mutant Melanoma

Erasca Reports Second Quarter 2024 Business Updates and Financial Results

Erasca to Present at Upcoming Investor Conferences in September

Erasca to Present Preliminary SEACRAFT-1 Phase 1 Data for Naporafenib Plus Trametinib in RAS Q61X Mutant Solid Tumors as Oral Presentation at 36th EORTC-NCI-AACR Symposium

Comments

Erasca

Erasca (ERAS) Opzioni

Erasca (NASDAQ:ERAS) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO